Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRM1, also known as Exportin 1 (XPO1), is the major nuclear export receptor in eukaryotic cells. It mediates the transport of proteins and RNAs from the nucleus to the cytoplasm, a process crucial for cellular homeostasis and gene expression regulation. CRM1 exports proteins with leucine-rich nuclear export signals (NES), ribosomal subunits, U snRNAs, rRNAs, some mRNAs, and other RNPs. Overexpression or mutation of CRM1 is implicated in various cancers, and it is a therapeutic target with inhibitors like selinexor showing promise in cancer treatment.
Inhibition of CRM1 by binding to C528 within the NES cleft, blocking nuclear export
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome Region Maintenance 1 (CRM1).